Möchten Sie immer auf dem neuesten Stand bleiben?

Clofutriben improved HbA1c and other cardiometabolic parameters in patients with Type 2 diabetes in a 6-week, placebo-controlled, randomized Phase 2 trial  Subset of participants with elevated...

Homeless Vets Welcome Here: AI City Hall Project Moves on Omni-AI Microcities (Veterans First for America)

SHENZHEN, CHINA, June 08, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative...

NEW ORLEANS, June 08, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, today announced results from a multi-center pivotal trial evaluating the safety and efficacy of the investigational twiist™...

MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model performed at thermoneutrality Weight loss and reduction of fat...

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel...

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance  New data expands on findings...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...